Treatment and Outcomes of Primary Pericardial Mesothelioma

A Contemporary Review of 103 Published Cases

Research output: Contribution to journalArticle

Abstract

Primary pericardial mesothelioma (PPM) is a rare cancer for which there is no consensus on treatment. We evaluated and summarized a large contemporary population of published PPM cases to characterize risk factors, treatment patterns, and clinical outcomes. Using Ovid and PubMed, literature published from 2000 through 2016 was searched using the terms “primary pericardial mesothelioma,” “pericardial mesothelioma,” and “malignant pericardial mesothelioma.” We identified 6 case series and 84 case reports for a total of 103 PPM cases published from 2000 through 2016. The median age at diagnosis was 55 years, and the median overall survival was 6 months. In univariate analyses of clinical characteristics including gender, asbestos exposure, tobacco use, prior radiation exposure, histologic subtype, and metastasis and/or mediastinal spread, only the presence of metastasis and/or mediastinal spread was a significant predictor of decreased survival (P =.015). Surgery did not provide a statistically significant survival benefit (P =.12). A survival benefit was noted in those who received chemotherapy (median survival, 13 months vs. 0.5 months, P =.002), specifically chemotherapy with a platinum agent with or without pemetrexed. In multivariate analysis, only the receipt of chemotherapy was associated with improved survival. PPM remains a rare and poorly understood malignancy with unclear etiology and a poor prognosis. In this retrospective systematic review, a survival benefit was seen in patients who received chemotherapy.

Original languageEnglish (US)
JournalClinical Lung Cancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Mesothelioma
Survival
Drug Therapy
Pemetrexed
Neoplasm Metastasis
Asbestos
Tobacco Use
Platinum
PubMed
Neoplasms
Consensus
Multivariate Analysis
Therapeutics
Population

Keywords

  • Asbestos
  • Clinical
  • Malignancy
  • Pericardium
  • Retrospective

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

@article{d54028424b0649b78da6c61e79c7e761,
title = "Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases",
abstract = "Primary pericardial mesothelioma (PPM) is a rare cancer for which there is no consensus on treatment. We evaluated and summarized a large contemporary population of published PPM cases to characterize risk factors, treatment patterns, and clinical outcomes. Using Ovid and PubMed, literature published from 2000 through 2016 was searched using the terms “primary pericardial mesothelioma,” “pericardial mesothelioma,” and “malignant pericardial mesothelioma.” We identified 6 case series and 84 case reports for a total of 103 PPM cases published from 2000 through 2016. The median age at diagnosis was 55 years, and the median overall survival was 6 months. In univariate analyses of clinical characteristics including gender, asbestos exposure, tobacco use, prior radiation exposure, histologic subtype, and metastasis and/or mediastinal spread, only the presence of metastasis and/or mediastinal spread was a significant predictor of decreased survival (P =.015). Surgery did not provide a statistically significant survival benefit (P =.12). A survival benefit was noted in those who received chemotherapy (median survival, 13 months vs. 0.5 months, P =.002), specifically chemotherapy with a platinum agent with or without pemetrexed. In multivariate analysis, only the receipt of chemotherapy was associated with improved survival. PPM remains a rare and poorly understood malignancy with unclear etiology and a poor prognosis. In this retrospective systematic review, a survival benefit was seen in patients who received chemotherapy.",
keywords = "Asbestos, Clinical, Malignancy, Pericardium, Retrospective",
author = "Elizabeth McGehee and Gerber, {David E} and Reisch, {Joan S} and Dowell, {Jonathan E}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.cllc.2018.11.008",
language = "English (US)",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",

}

TY - JOUR

T1 - Treatment and Outcomes of Primary Pericardial Mesothelioma

T2 - A Contemporary Review of 103 Published Cases

AU - McGehee, Elizabeth

AU - Gerber, David E

AU - Reisch, Joan S

AU - Dowell, Jonathan E

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Primary pericardial mesothelioma (PPM) is a rare cancer for which there is no consensus on treatment. We evaluated and summarized a large contemporary population of published PPM cases to characterize risk factors, treatment patterns, and clinical outcomes. Using Ovid and PubMed, literature published from 2000 through 2016 was searched using the terms “primary pericardial mesothelioma,” “pericardial mesothelioma,” and “malignant pericardial mesothelioma.” We identified 6 case series and 84 case reports for a total of 103 PPM cases published from 2000 through 2016. The median age at diagnosis was 55 years, and the median overall survival was 6 months. In univariate analyses of clinical characteristics including gender, asbestos exposure, tobacco use, prior radiation exposure, histologic subtype, and metastasis and/or mediastinal spread, only the presence of metastasis and/or mediastinal spread was a significant predictor of decreased survival (P =.015). Surgery did not provide a statistically significant survival benefit (P =.12). A survival benefit was noted in those who received chemotherapy (median survival, 13 months vs. 0.5 months, P =.002), specifically chemotherapy with a platinum agent with or without pemetrexed. In multivariate analysis, only the receipt of chemotherapy was associated with improved survival. PPM remains a rare and poorly understood malignancy with unclear etiology and a poor prognosis. In this retrospective systematic review, a survival benefit was seen in patients who received chemotherapy.

AB - Primary pericardial mesothelioma (PPM) is a rare cancer for which there is no consensus on treatment. We evaluated and summarized a large contemporary population of published PPM cases to characterize risk factors, treatment patterns, and clinical outcomes. Using Ovid and PubMed, literature published from 2000 through 2016 was searched using the terms “primary pericardial mesothelioma,” “pericardial mesothelioma,” and “malignant pericardial mesothelioma.” We identified 6 case series and 84 case reports for a total of 103 PPM cases published from 2000 through 2016. The median age at diagnosis was 55 years, and the median overall survival was 6 months. In univariate analyses of clinical characteristics including gender, asbestos exposure, tobacco use, prior radiation exposure, histologic subtype, and metastasis and/or mediastinal spread, only the presence of metastasis and/or mediastinal spread was a significant predictor of decreased survival (P =.015). Surgery did not provide a statistically significant survival benefit (P =.12). A survival benefit was noted in those who received chemotherapy (median survival, 13 months vs. 0.5 months, P =.002), specifically chemotherapy with a platinum agent with or without pemetrexed. In multivariate analysis, only the receipt of chemotherapy was associated with improved survival. PPM remains a rare and poorly understood malignancy with unclear etiology and a poor prognosis. In this retrospective systematic review, a survival benefit was seen in patients who received chemotherapy.

KW - Asbestos

KW - Clinical

KW - Malignancy

KW - Pericardium

KW - Retrospective

UR - http://www.scopus.com/inward/record.url?scp=85059036927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059036927&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2018.11.008

DO - 10.1016/j.cllc.2018.11.008

M3 - Article

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -